Introduction
============

COPD is a serious chronic disease. Because of its diversity and heterogeneity, individualized assessment and management are needed.[@b1-copd-13-121],[@b2-copd-13-121] Frequent exacerbations (FEs) mean that the disease is progressing faster, increasing the risk of acute re-exacerbation and mortality.[@b1-copd-13-121],[@b2-copd-13-121] Therefore, the accurate prediction of recurrent COPD exacerbation has great significance to determine the progression and prognosis.

Most of the Chinese patients with COPD are at high risk of exacerbation, with a mean of two acute exacerbation events each year.[@b3-copd-13-121] Another study showed that the annual number of exacerbation events in Chinese patients was about 0.5--3.5.[@b4-copd-13-121] Before 2011, forced expiratory volume in 1 second (FEV~1~) was considered as a significant prognostic factor of COPD, and the frequency of acute exacerbation of COPD (AECOPD), hospitalization rate, and mortality of COPD were associated with altered lung function.[@b5-copd-13-121] More recent studies showed that ≥2 events/year of AECOPD[@b1-copd-13-121] or ≥1 event/year of AECOPD leading to hospitalization[@b6-copd-13-121] was the risk factor for future exacerbation events. The 2017 Global Initiative for Chronic Obstructive Lung Disease \[GOLD\] guidelines[@b7-copd-13-121] reemphasized that patients with AECOPD and AECOPD events during hospitalization were important evidence for assessing the risk of future exacerbations.

Chest computed tomography (CT) can provide some data about the pathological changes of COPD. Some indicators (such as emphysema index \[EI\]) have a good correlation with pulmonary function test (PFT) parameters and mortality from COPD.[@b8-copd-13-121] The COPDGene study showed that wall thickness and emphysema were involved in AECOPD and were independent of airflow limitation.[@b9-copd-13-121] Many methods have been studied for forecasting AECOPD[@b10-copd-13-121] and mortality,[@b11-copd-13-121] but COPD is a heterogeneous disease, and these methods were not adopted because of their limitations and because a single index based on punctual clinical, imaging, pulmonary function, and biological markers cannot reflect the whole picture of the disease. Therefore, more reliable tools are necessary to predict AECOPD. Among others, wall thickness and EI, two imaging features, are well-accepted indicators reflecting the pathological changes of COPD.[@b12-copd-13-121],[@b13-copd-13-121] CT is the preferred imaging technique to image small areas of emphysema and to assess the seriousness of emphysema and COPD.[@b12-copd-13-121],[@b13-copd-13-121] However, it remains unknown if CT features of COPD can predict hospitalization due to AECOPD.

Therefore, the aims of the current study were: 1) to compare the differences in clinical symptom scores, inflammatory markers, lung function indicators, and CT parameters between patients frequently vs infrequently hospitalized for AECOPD events and 2) to identify the factors associated with acute exacerbation leading to hospitalization.

Patients and methods
====================

Study design and subjects
-------------------------

This was a retrospective study of consecutive patients with COPD hospitalized at the Department of Respiratory Medicine of the Ninth Hospital of Xi'an Affiliated Hospital of Xi'an Jiaotong University between October 2014 and September 2016, meeting the GOLD diagnostic criteria (FEV~1~/forced vital capacity \[FVC\] \<70% after bronchodilator inhalation).[@b14-copd-13-121] The exclusion criteria were as follows: 1) \<40 years of age; 2) pregnant woman; 3) comorbid lung diseases such as lung cancer, pneumonia, active pulmonary tuberculosis, pulmonary embolism, or interstitial lung disease; 4) previous lung surgery; 5) unable to complete PFT; 6) asthma, severe heart, liver, or kidney dysfunction; or 7) high-resolution CT (HRCT) quality was insufficient for analysis.

The study is a substudy of the "Digital Lung" Respiratory Disease Evaluation System and Diagnostic Criteria (201402013) approved by the Chinese Clinical Research Registry (approval number ChiCTR-OCH-14004904). The study was approved by the ethics committee of the Ninth Hospital of Xi'an (No 2014001). The need for individual informed consent was waived by the committee because of the retrospective nature of the study, and the medical data accessed were de-identified.

Grouping
--------

During follow-up after the hospitalization, the patients who had been rehospitalized within 1 year for AECOPD were grouped into the FE group, while the ones who were not hospitalized in the following year were grouped into the infrequent exacerbation (IE) group.

Data collection
---------------

After enrollment, sex, age, smoking status (former smokers, never smokers, and current smokers), place of residence, COPD health education (both education to the general population and specialized education to the COPD patients), body mass index (BMI), and the number of hospitalization due to AECOPD in the past year were collected. The COPD Assessment Test (CAT) and the modified Medical Research Council (mMRC) dyspnea index were collected from the medical charts.

PFT
---

The PFT was performed just before discharge, at which time the patients had no symptoms of wheezing. Spirometry and impulse oscillometry system (IOS) (MasterScreen, Jaeger, Germany) were performed. Maximum expiratory flow--volume curve, FVC, pulmonary diffusion function in one breath, and bronchial diastolic function were evaluated after administration of 200 μg of salbutamol. The procedure was performed according to the American Thoracic Society/European Respiratory Society guidelines.[@b15-copd-13-121]

Biochemistry
------------

Blood was sampled within 3 days of admission. White blood cells, hemoglobin, neutrophil ratio, eosinophil ratio, and platelet count were measured using an automatic blood cell analyzer (BC-6800; Mindray Bio Medical Electronics Co., Ltd, Shenzhen, People's Republic of China). C-reactive protein (CRP) was measured using a Siemens automatic protein analyzer (BN ProSpec; Siemens, Erlangen, Germany). Fibrinogen was measured using an automatic coagulation analyzer (STA-R Evolution; Diagnostica Stago, Paris, France). Blood gas analysis was performed using a Radiometer ABL Fully Automatic Blood Gas Analyzer (ABL800; Radiometer, Copenhagen, Denmark). Procalcitonin was measured using a BioMerieux Automatic Fluorescence Immunoassay (Mini Vidas; BioMerieux, Marcy l'Étoile, France).

CT examinations were performed using a 64-detector CT (Somatom Definition AS; Siemens) with subjects holding their breath at full inspiration in the supine position. Tube voltage was 120 kV, and tube current varied by automatic methods based on slice location and participants' body habitus. The exposure time was 0.5 second, and the matrix size was 512×512 pixels. Images were contiguously reconstructed with a 1 mm slice thickness (with 0.625 mm overlapping), using a standard kernel algorithm.

All CT images were automatically analyzed using the FACT-Digital Lung software.[@b16-copd-13-121],[@b17-copd-13-121] The percentage of the wall area (%WA) of different generations of bronchi in each lobe was calculated as the %WA of the fourth to seventh generations of the right upper lobe (RUL), left upper lobe (LUL), and right middle lobe (RML), and as the %WA of the fourth to ninth generations of the right lower lobe (RLL) and left lower lobe (LLL), represented as %WA~RUL4--7~, %WA~LUL4--7~, %WA~RML4--7~, %WA~RLL4--9~, and %WA~LLL4--9~, respectively. The measurement method is shown in [Figure 1A](#f1-copd-13-121){ref-type="fig"}. The extents of emphysema were quantified by the percentage of lung volumes with CT attenuation value below −950 HU (%LAA-950) on the inspiratory images. %LAA-950 was defined as the EI, according to the literature.[@b18-copd-13-121],[@b19-copd-13-121] EI \>10% was defined as the COPD emphysema threshold. The emphysema of whole lung, right lung, left lung, and each lobe was calculated and represented as %LAA~whole~, %LAA~right\ lung~, %LAA~left\ lung~, %LAA~RUL~, %LAA~RML~, %LAA~RLL~, %LAA~LUL~, and %LAA~LLL~, respectively. Because of the limitations of CT accuracy, EI values \<5% were filtered out.[@b18-copd-13-121],[@b19-copd-13-121] The mean emphysema density (MED) of whole lung, right lung, left lung, and each lobe was represented as MED~whole~, MED~right\ lung~, MED~left\ lung~, MED~RUL~, MED~RML~, MED~RLL~, MED~LUL~, and MED~LLL~, respectively. The measurement method is shown in [Figure 1B](#f1-copd-13-121){ref-type="fig"}. An emphysema heterogeneity index (HI) ranging from −1 to +1 between the upper and lower lobes was computed, based on a prior paper.[@b20-copd-13-121] When emphysema was equally distributed among the lobes or the full extent of the whole lung was \<1%, the HI was near zero; otherwise, HI = (%LAA~upper~ − %LAA~lower~)/(%LAA~upper~ + %LAA~lower~)\*100%.[@b17-copd-13-121] Values close to 0 indicated the uniformity of emphysema change. Values close to +1 indicated superiority of upper emphysema. Values close −1 indicated superiority of lower emphysema. %WA was used as an index of bronchial wall thickness. EI was an indicator of the extent of emphysema. MED was an indicator of the degree of emphysema. HI was an indicator of the distribution of emphysema.

Statistical analysis
--------------------

Statistical analysis was performed using SPSS 19.0 (IBM Corporation, Armonk, NY, USA). Two-sided *P*-values \<0.05 were deemed statistically significant. Continuous data were tested for normality using the Kolmogorov--Smirnov test. Data meeting the normal distribution were expressed as mean ± SD and were analyzed using the Student's *t*-test. Non-normally distributed data were expressed as median (range) and analyzed using the Mann--Whitney *U* test. Categorical data were expressed as proportions and analyzed using the chi-square test. Binary logistic regression models were used to identify predictive factors for FE using a stepwise method, with a probability value for the entry of *P*=0.10 and removal of *P*=0.05.

Results
=======

Patients
--------

A total of 286 patients were included; 21 did not complete the PFTs, 12 patients failed to meet CT quality requirements, and data were missing for 10 patients. Therefore, 243 patients were included in the analyses ([Figure 2](#f2-copd-13-121){ref-type="fig"}).

Characteristics of the patients
-------------------------------

Compared with the IE group, the FE group showed more exacerbation hospitalizations in the following year (*P*\<0.001), higher mMRC classification (*P*=0.003), higher white blood cells (*P*=0.026), higher arterial blood carbon dioxide partial pressure (PaCO~2~; *P*=0.002), more comorbidities (*P*=0.032), and higher proportion of patients with GOLD grade 4 (*P*=0.048). No significant differences were found in age, sex, place of residence, smoking status, BMI, CAT, neutrophil ratio, eosinophil ratio, hemoglobin, platelet, fibrinogen, CRP, and arterial oxygen partial pressure (PaO~2~; [Table 1](#t1-copd-13-121){ref-type="table"}). Overall, these results suggest that patients in the FE group had a lower health status compared with the IE group.

Comparison of PFT between FE and IE hospitalization
---------------------------------------------------

Compared with the IE group, the FE group had lower FEV~1~/FVC (*P*=0.005), FEV~1%pred~ (*P*=0.002), maximal mid-expiratory flow (MMEF~25--75%pred~) (*P*=0.003), and DLCO/VA (*P*=0.03) and higher response frequency (F~res~; *P*=0.04). Residual volume/total lung capacity (RV/TLC), total respiratory impedance (Z~5%pred~), resistance at 5 Hz-resistance at 20 Hz (R~5~--R~20~), reactance at 5 Hz (X~5~), and reactance area (Ax) did not show significant differences (*P*\>0.05; [Table 2](#t2-copd-13-121){ref-type="table"}). These results indicate lower pulmonary functions in patients of the FE group.

Comparison of %WA, %LLA, MED, and HI between FE and IE
------------------------------------------------------

Compared with the IE group, the FE group had more %WA~RUL4~ (0.63 \[0.58--0.66\] vs 0.60 \[0.55--0.65\], *P*=0.026); %WA~RML4~ (0.56±0.09 vs 0.53±0.08, *P*=0.019); %WA~RLL5~ (0.57±0.06 vs 0.55±0.06, *P*=0.008); %WA~LUL4~ (0.59±0.08 vs 0.57±0.07, *P*=0.031); %WA~LLL4~ (0.56±0.07 vs 0.53±0.07, *P*=0.019); and %WA~LLL5~ (0.64 \[0.59--0.67\] vs 0.61 \[0.57--0.65\], *P*=0.021; [Table 3](#t3-copd-13-121){ref-type="table"}).

Compared with the IE group, the EI of the whole lung, right lung, left lung, and each lung lobe in the FE group were higher: %LAA~whole~ (9.88 \[1.82--18.58\] vs 5.92 \[1.53--11.21\], *P*=0.014); %LAA~right\ lung~ (9.47 \[1.94--18.13\] vs 5.58 \[1.19--10.83\], *P*=0.011); %LAA~left\ lung~ (9.43 \[1.84--19.02\] vs 4.85 \[1.42--10.27\], *P*=0.018); %LAA~RUL~ (9.45 \[1.72--23.21\] vs 5.1 \[1.03--11.3\], *P*=0.022); %LAA~RML~ (8.97 \[3.75--17.64\] vs 4.39 \[1.15--11.34\], *P*=0.004); %LAA~RLL~ (6.04 \[1.52--12.93\] vs 3.59 \[0.74--9\], *P*=0.024); %LAA~LUL~ (7.69 \[2.27--22.39\] vs 5.06 \[1.5--12.88\], *P*=0.045); and %LAA~LLL~ (7.44 \[1.69--13.58\] vs 3.64 \[0.7--9.86\], *P*=0.018; [Table 3](#t3-copd-13-121){ref-type="table"}).

MED~whole~ and MED~left\ lung~ in the FE group were significantly worse than in the IE group (*P*\<0.05). Further analysis in each lobe showed emphysema density difference in MED~RUL~ (*P*=0.03) and MED~LLL~ (*P*=0.02). There were no differences in MED~right\ lung~ MED~RML~, MED~RUL~, and MED~LLL~ (*P*\>0.05). Unexpectedly, HI (which represents emphysema distribution) was not different between the FE and IE groups (all *P*\>0.05; [Table 3](#t3-copd-13-121){ref-type="table"}). Overall, these results suggest that worst imaging features of emphysema, ie, %WA, %LLA, and MED, were associated with more FEs of COPD.

Factors influencing FE hospitalization
--------------------------------------

The GOLD guidelines suggest that FEV~1~ is a predictor of poor prognosis; mMRC ≥2 is the recommended cutoff value for the classification of symptoms; and white cell counts (\>10×10^9^), PaCO~2~ \>45 mmHg, and X~5~ negative value increase \<0 are reference values for pulmonary functions.[@b1-copd-13-121],[@b7-copd-13-121] EI \>10% was determined according to Hersh et al[@b18-copd-13-121] and Xie et al.[@b19-copd-13-121]

Seven variables were included in the logistic regression model: exacerbation hospitalizations in the past year (≥1), FEV~1%pred~ (\<50%), mMRC (≥2), comorbidities (≥1), white cell counts (\>10×10^9^), and EI (\>10%). Using the stepwise method, exacerbation hospitalizations in the past year and EI \>10% were independently associated with frequent AECOPD hospitalization ([Table 4](#t4-copd-13-121){ref-type="table"}).

Discussion
==========

COPD is a heterogeneous disease, and the available prognostic indexes are therefore limited. This study aimed to identify the factors associated with AECOPD leading to hospitalization. The results suggest that exacerbation hospitalizations in the past year and EI were independently associated with FE hospitalization. Wall thickness and EI, two imaging features, are well-accepted indicators reflecting the pathological changes of COPD.[@b12-copd-13-121],[@b13-copd-13-121],[@b21-copd-13-121] EI is more sensitive, while wall thickness can only be applied for major airways; hence, the contribution of small airway in the evaluation of COPD is limited. Nevertheless, the changes in the major airways can reflect the changes in the small airways. Therefore, the current study investigated COPD from the range and distribution of emphysema to explore the relationship with frequent hospitalization caused by acute exacerbation, which has never been reported before.

Previous studies of the readmissions for AECOPD identified a number of risk factors. Bahadori et al[@b22-copd-13-121] identified preadmission oxygen use, history of lung infection, other chronic respiratory disease, and shorter hospital stay as risk factors for readmission for AECOPD. A review identified more severe COPD as the main factor for rehospitalization, as well as older age, increased breathlessness, poor general condition, cyanosis, peripheral edema, impaired consciousness, poor coping at home, significant comorbidities, and failure to initial treatments.[@b23-copd-13-121] Another study reported that respiratory rate, heart rate, and oxygen saturation are factors for rehospitalization.[@b24-copd-13-121] These studies did not directly examine CT features of COPD as risk factor for rehospitalization.

The current study showed that the COPD of patients with FE hospitalization showed more obvious symptoms of dyspnea, inflammation, and ventilation disorder, more comorbidities, and worse pulmonary function. In addition, CT analysis showed that the destruction of the parenchyma of whole lung, right lung, left lung, and all five lung lobes was more pronounced in FE patients. Furthermore, the mean density of emphysema was more severe in the RUL and LLL. Finally, exacerbation hospitalizations in the past year and EI were independently associated with hospitalization. These results are supported by a cohort study that showed that with the increase in the number of hospitalizations, the risk of acute exacerbation and death increased in turn.[@b25-copd-13-121] The ECLIPSE study also showed that the three-year mortality rate was much higher in patients with AECOPD hospitalization than in those without AECOPD hospitalization.[@b26-copd-13-121] Therefore, the prediction of frequent acute exacerbation of hospitalization is vital to the management of COPD.

HRCT imaging allows objective measurements of the pathological damages of COPD (peripheral airway stenosis, airflow limitation, emphysema structural changes, etc). The severity of emphysema is associated with increased health deterioration and increased mortality.[@b27-copd-13-121],[@b28-copd-13-121] Peripheral airway wall thickness is associated with pulmonary function and acute exacerbations.[@b27-copd-13-121],[@b29-copd-13-121] Therefore, CT data on COPD pathological damage and subtype assessment are of great significance. The current study showed that the emphysema range of the FE group was obviously more important than that of the IE group, and that the severity of emphysema was especially high in the upper right and lower left lobes. The parenchyma destruction could be used as an indicator of the progression of COPD. Previous studies have shown that the distribution of emphysema is heterogeneous,[@b30-copd-13-121],[@b31-copd-13-121] and the superior lung distribution of COPD suggests that a subgroup of patients may benefit from lung reduction surgery. On the other hand, the current study showed that the HI of emphysema was not associated with FE hospitalization.

Each leaf of the proximal bronchus (fourth and fifth generations) wall area percentage of the FE group was obviously increased compared to that of the IE group, but the distal bronchus (sixth to ninth generations) wall area was not found to be different between the two groups. The airway can respond to small airway inflammation, and small airway measurements have never been suitable for clinical assessments. The current study showed that the detection of airway morphological changes may have a certain clinical usefulness.

Although FEV~1~ is considered to be unable to provide the whole COPD picture and is not a reliable predictor for a specific individual,[@b32-copd-13-121] this is controversial. Indeed, the ECLIPSE study suggested that the grade of lung function, COPD mortality, and previous year hospitalization were higher in patients with FE.[@b26-copd-13-121] In the current study, FEV~1~ and other lung function parameters could not predict frequent AECOPD hospitalization. FEV~1~ mainly reflects the obstruction of the large airways and is not sensitive to the obstruction of the small airway.

It has been reported that the base CAT value can be highly accurate to predict the time of the first acute exacerbation.[@b21-copd-13-121] The risk of death in COPD with cough and expectoration is reported to increase significantly.[@b33-copd-13-121] A study found that the risk of AECOPD increased with the simultaneous increase in baseline CRP, fibrinogen, and white blood cell count.[@b34-copd-13-121] In the current study, mMRC, white blood cell count, and PaCO~2~ were higher in the FE group than in the IE group, indicating that FE may be associated with more dyspnea symptoms, inflammation, and ventilation disorders. Nevertheless, neither CAT nor mMRC were associated with the risk of future exacerbation hospitalizations, as supported with a previous study.[@b5-copd-13-121]

The current study is not without limitations. The follow-up period was short, only 1 year. Second, the number of inflammatory indicators was limited, and no inflammatory indicator could be associated with acute exacerbation. Finally, the sample size was small. Additional studies are still necessary to identify the risk factors for AECOPD.

Conclusion
==========

In addition to exacerbation hospitalizations in the past year, imaging parameters, including the EI (\>10%), have a certain value in predicting FE hospitalization.
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![(**A**) CT software measurement of the bronchial wall thickness. (**B**) CT software measurement of the lung density. The bronchial tree was first identified. Then, the generations of bronchus were identified, after which the mean wall thickness of each generation of bronchus, as well as the other parameters, was measured. The results of the measurements are shown in the left panel. The whole lung and the different lobes are shown. The measurements of the lung density (HU) are shown in different colors.\
**Abbreviation:** CT, computed tomography.](copd-13-121Fig1){#f1-copd-13-121}

![Patient flowchart.\
**Abbreviations:** AECOPD, acute exacerbation of COPD; CT, computed tomography; FE, frequent exacerbation; IE, infrequent exacerbation; PFT, pulmonary function test.](copd-13-121Fig2){#f2-copd-13-121}

###### 

Demographic and clinical characteristics of the patients

  Variables                FE (n=111)            IE (n=132)           *P*-value
  ------------------------ --------------------- -------------------- ----------------------------------------------------
  Male                     104 (93.7%)           119 (90.2%)          0.317[a](#tfn1-copd-13-121){ref-type="table-fn"}
  Age (years)              68.44±10.1            67.42±10.11          0.432[b](#tfn2-copd-13-121){ref-type="table-fn"}
  Live the city            102 (91.9%)           121 (91.7%)          0.949[a](#tfn1-copd-13-121){ref-type="table-fn"}
  COPD education           50 (45%)              33 (25%)             0.001[a](#tfn1-copd-13-121){ref-type="table-fn"}
  Smokers                  91 (82%)              99 (75%)             0.189[a](#tfn1-copd-13-121){ref-type="table-fn"}
  Current smokers          40 (36%)              52 (39.4%)           0.591[a](#tfn1-copd-13-121){ref-type="table-fn"}
  Pack/years               40 (20--50)           40 (25--60)          0.228[c](#tfn3-copd-13-121){ref-type="table-fn"}
  BMI (kg/m^2^)            23.15±3.73            23.20±4.00           0.927[b](#tfn2-copd-13-121){ref-type="table-fn"}
  Hypertension             52 (46.8%)            53 (40.2%)           0.294[a](#tfn1-copd-13-121){ref-type="table-fn"}
  Coronary heart disease   49 (44.1%)            39 (29.5%)           0.018[a](#tfn1-copd-13-121){ref-type="table-fn"}
  Diabetes                 21 (18.9%)            13 (9.8%)            0.042[a](#tfn1-copd-13-121){ref-type="table-fn"}
  Comorbidities            81 (73%)              79 (59.8%)           0.032[a](#tfn1-copd-13-121){ref-type="table-fn"}
  CAT                      21 (15--26)           21 (15.25--26)       0.986[c](#tfn3-copd-13-121){ref-type="table-fn"}
  mMRC                     2 (1--3)              1 (0--1)             0.003[c](#tfn3-copd-13-121){ref-type="table-fn"}
  Exacerbations/year       1 (1--2)              0 (0--0)             \<0.001[c](#tfn3-copd-13-121){ref-type="table-fn"}
  WBC (×10^9^/L)           6.33 (5.10--7.73)     7.03 (5.61--8.70)    0.026[c](#tfn3-copd-13-121){ref-type="table-fn"}
  N (%)                    72.15 (63.5--80.5)    70.7 (62.2--79.1)    0.48[c](#tfn3-copd-13-121){ref-type="table-fn"}
  E (%)                    1.45 (0.4--3.53)      1.60 (0.3--3.20)     0.899[c](#tfn3-copd-13-121){ref-type="table-fn"}
  HB (g/L)                 145.5 (131--157.25)   141 (129--152)       0.11[c](#tfn3-copd-13-121){ref-type="table-fn"}
  PLT (×10^9^/L)           153.5 (123.75--199)   167 (134--218)       0.06[c](#tfn3-copd-13-121){ref-type="table-fn"}
  FIB, g/L                 3.79 (3.04--4.63)     3.86 (3.14--4.90)    0.587[c](#tfn3-copd-13-121){ref-type="table-fn"}
  CRP, mg/L                6.55 (3.28--25.40)    8.25 (3.28--30.43)   0.545[c](#tfn3-copd-13-121){ref-type="table-fn"}
  pH                       7.41 (7.38--7.44)     7.42 (7.40--7.44)    0.095[c](#tfn3-copd-13-121){ref-type="table-fn"}
  PaO~2~, mmHg             75.5 (65--86)         73 (66--87.75)       0.989[c](#tfn3-copd-13-121){ref-type="table-fn"}
  PaCO~2~, mmHg            43 (38--53.5)         40 (35--45)          0.002[c](#tfn3-copd-13-121){ref-type="table-fn"}
  GOLD grade 1             7 (6.3%)              11 (8.3%)            0.548[a](#tfn1-copd-13-121){ref-type="table-fn"}
  GOLD grade 2             31 (27.9%)            51 (38.6%)           0.079[a](#tfn1-copd-13-121){ref-type="table-fn"}
  GOLD grade 3             48 (43.2%)            53 (40.2%)           0.626[a](#tfn1-copd-13-121){ref-type="table-fn"}
  GOLD grade 4             25 (22.5%)            17 (12.9%)           0.048[a](#tfn1-copd-13-121){ref-type="table-fn"}
  FEV~1%pred~\<50%         73 (65.8%)            70 (53%)             0.045[a](#tfn1-copd-13-121){ref-type="table-fn"}

**Notes:**

Chi-square test.

*t*-test;

Mann--Whitney *U* test.

**Abbreviations:** BMI, body mass index; CAT, COPD Assessment Test; CRP, C-reactive protein; E, eosinophil; FE, frequent exacerbation; FEV~1~, forced expiratory volume in 1 second; FIB, fibrinogen; GOLD, Global Initiative for Chronic Obstructive Lung Disease; HB, hemoglobin; IE, infrequent exacerbation; mMRC, modified Medical Research Council; N, neutrophil; PLT, platelet; WBC, white blood cell.

###### 

Comparison of PFT between the FE and IE groups

  Parameters                     FE                       IE                      *P*-value
  ------------------------------ ------------------------ ----------------------- -----------
  FEV~1~                         1.14 (0.81--1.47)        1.35 (0.94--1.74)       0.002
  FEV~1%pred~                    38.2 (30.6--54.7)        49.6 (36.88--60.4)      0.002
  FEV~1~/FVC                     48.21 (42.75--58.65)     54.99 (46.09--60.81)    0.005
  MMEF~25--75%pred~              15.3 (11.2--23.6)        19.7 (13.98--27.2)      0.003
  DLCO/VA                        75.7 (57.42--99.15)      86.7 (67.08--100.95)    0.03
  RV/TLC                         57.39±11.21              55.52±9.55              0.167
  Z~5~%Pred                      183.6 (147.4--218.9)     170.9 (137.1--204.3)    0.116
  R~5~                           0.50 (0.42--0.59)        0.49 (0.39--0.59)       0.224
  R~20~                          0.32 (0.29--0.37)        0.31 (0.28--0.38)       0.66
  R~5~--R~20~                    0.19 (0.12--0.24)        0.16 (0.1--0.23)        0.105
  X~5~                           −0.24 (−0.34 to −0.17)   −0.22 (−0.30 to 0.13)   0.084
  X~5~ negative value increase   −0.01 (−0.1--0)          0 (−0.08--0)            0.217
  F~res~                         23.16±5.43               21.69±5.57              0.04
  Ax                             1.93 (1.2--2.83)         1.73 (0.95--2.57)       0.096

**Notes:** Mann--Whitney *U* test. Ax, reactance area; %Pred, of the predicted value; R~5~, resistance at 5 Hz; R~20~, resistance at 20 Hz; X~5~, reactance at 5 Hz; Z~5~, total respiratory impedance. DLCO/VA, ratio of carbon monoxide diffusion capacity to alveolar ventilation.

**Abbreviations:** FE, frequent exacerbation; FEV~1~, forced expiratory volume in 1 second; F~res~, response frequency; FVC, forced vital capacity; IE, infrequent exacerbation; MMEF~25--75%pred~, maximal mid-expiratory flow; PFT, pulmonary function test; RV/TLC, residual volume/total lung capacity.

###### 

Comparison of CT parameters between the FE and IE groups

  Wall areas   FE                  IE                  *P*-value   Emphysema           FE                             IE                             *P*-value
  ------------ ------------------- ------------------- ----------- ------------------- ------------------------------ ------------------------------ -----------
  %WA~RUL4~    0.63 (0.58--0.66)   0.60 (0.55--0.65)   0.026       %LAA~whole~         9.88 (1.82--18.58)             5.92 (1.53--11.21)             0.014
  %WA~RUL5~    0.73 (0.7--0.77)    0.72 (0.67--0.75)   0.086       %LAA~right\ lung~   9.47 (1.94--18.13)             5.58 (1.19--10.83)             0.011
  %WA~RUL6~    0.79 (0.76--0.82)   0.79 (0.75--0.82)   0.629       %LAA~left\ lung~    9.43 (1.84--19.02)             4.85 (1.42--10.27)             0.018
  %WA~RUL7~    0.81 (0.76--0.84)   0.82 (0.77--0.86)   0.153       %LAA~RUL~           9.45 (1.72--23.21)             5.1 (1.03--11.3)               0.022
  %WA~RML4~    0.56±0.09           0.53±0.08           0.019       %LAA~RML~           8.97 (3.75--17.64)             4.39 (1.15--11.34)             0.004
  %WA~RML5~    0.67±0.08           0.66±0.07           0.511       %LAA~RLL~           6.04 (1.52--12.93)             3.59 (0.74--9)                 0.024
  %WA~RML6~    0.73 (0.69--0.77)   0.74 (0.68--0.78)   0.32        %LAA~LUL~           7.69 (2.27--22.39)             5.06 (1.5--12.88)              0.045
  %WA~RML7~    0.76 (0.70--0.81)   0.75 (0.70--0.78)   0.463       %LAA~LLL~           7.44 (1.69--13.58)             3.64 (0.7--9.86)               0.018
  %WA~RLL4~    0.45 (0.42--0.48)   0.44 (0.40--0.47)   0.098       MED~whole~          −982.77 (−984.63 to −980.89)   −981.87 (−983.7 to −979.88)    0.042
  %WA~RLL5~    0.57±0.06           0.55±0.06           0.008       MED~right\ lung~    −982.36 (−984.68 to −980.37)   −981.48 (−983.77 to −979.31)   0.063
  %WA~RLL6~    0.65 (0.6--0.69)    0.65 (0.6--0.7)     0.933       MED~left\ lung~     −983.51 (−984.96 to −980.83)   −982.02 (−984.21 to −979.99)   0.025
  %WA~RLL7~    0.67±0.08           0.65±0.07           0.1         MED~RUL~            −982.77±3.54                   −981.56±3.42                   0.03
  %WA~RLL8~    0.68±0.07           0.67±0.05           0.184       MED~RML~            −981.38 (−983.74 to −979.68)   −980.77 (−983.07 to −979.26)   0.15
  %WA~RLL9~    0.69±0.07           0.71±0.07           0.13        MED~RLL~            −982.36 (−985 to −979.6)       −980.93 (−983.79 to −979.25)   0.183
  %WA~LUL4~    0.59±0.08           0.57±0.07           0.031       MED~LUL~            −982.79 (−984.88 to −980.72)   −981.66 (−983.57 to −980.17)   0.051
  %WA~LUL5~    0.68 (0.64--0.71)   0.67 (0.63--0.71)   0.379       MED~LLL~            −983.47 (−985.62 to −981.26)   −981.83 (−984.77 to −979.8)    0.02
  %WA~LUL6~    0.73±0.05           0.74±0.06           0.25        HI~whole~           0.13±0.27                      0.13±0.28                      0.941
  %WA~LUL7~    0.79±0.05           0.78±0.06           0.304       HI~right\ lung~     0.17±0.29                      0.15±0.32                      0.787
  %WA~LLL4~    0.56±0.07           0.53±0.07           0.019       HI~left\ lung~      −0.19 (−0.41 to 0.02)          −0.08 (−0.31 to 0.09)          0.17
  %WA~LLL5~    0.64 (0.59--0.67)   0.61 (0.57--0.65)   0.021                                                                                         
  %WA~LLL6~    0.63 (0.57--0.67)   0.61 (0.55--0.65)   0.063                                                                                         
  %WA~LLL7~    0.68±0.07           0.70±0.06           0.93                                                                                          
  %WA~LLL8~    0.70±0.06           0.72±0.07           0.127                                                                                         
  %WA~LLL9~    0.71±0.07           0.73±0.07           0.349                                                                                         

**Notes:** %LAA, the extent of emphysema of CT attenuation value below −950 HU; the %WA of different generations in each lobe was represented as %WA~RUL4--7~, %WA~RML4--7~, %WA~RLL4--9~, %WA~LUL4--7~, and %WA~LLL4--9~. When emphysema is equally distributed among the lobes or the full extent in the whole lung is \<1%, HI is near zero; otherwise, HI = (%LAA~upper~ − %LAA~lower~)/(%LAA~upper~ + %LAA~lower~)×100.

**Abbreviations:** CT, computed tomography; FE, frequent exacerbation; HI, emphysema heterogeneity index; IE, infrequent exacerbation; LLL, left lower lobe; LUL, left upper lobe; MED, mean emphysema density; RLL, right lower lobe; RML, right middle lobe; RUL, right upper lobe; %WA, the percentage of the wall area.

###### 

Logistic regression analysis of factors associated with FE hospitalization

                                                   *P*-value   OR (95% CI)
  ------------------------------------------------ ----------- ------------------------
  Exacerbation hospitalizations in the past year   \<0.001     14.419 (6.107--34.043)
  EI (\>10%)                                       0.016       2.947 (1.226--7.085)

**Abbreviations:** EI, emphysema index; FE, frequent exacerbation; OR, odds ratio.

[^1]: These authors contributed equally to this work
